KRAS and pancreatic neoplasm: Compared to the wild-type KRAS-mutation containing human pancreatic cancer cells, human pancreatic cancer cells containing the KRASG12D mutation displayed an increased CDK5 kinase activity and enhanced p35 cleavage, which contribute to early stage PDAC progression (Eggers et al., 2011).